Scientific Literature

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

In the past decade, advances in the use of monoclonal antibodies (mAbs) and adoptive cellular therapy to treat cancer by modulating the immune response have led to unprecedented responses in patients with advanced-stage tumours that would otherwise have been fatal.

Khalil DN, Smith EL, Brentjens RJ, Wolchok JD.
Nat Rev Clin Oncol. 2016 May;13(5):273-90.

Learn More

Immunotherapy of Melanoma.

The history of immunotherapy is rooted in the treatment of melanoma and therapy with immune checkpoint-blocking agents is now a cornerstone for the treatment of metastatic melanoma.

Snyder A, Zamarin D, Wolchok JD.
Prog Tumor Res. 2015;42:22-9.

Learn More

PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells.

Over expression of various immunogenic melanoma associated antigens (MAAs) has been exploited in the development of immunotherapeutic melanoma vaccines.

George AL, Suriano R, Rajoria S, Osso MC, Tuli N, Hanly E, Geliebter J, Arnold AN, Wallack M, Tiwari RK.
J Cancer. 2015 Oct 29;6(12):1320-30.

Learn More

Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma.

Development of a melanoma-specific vaccine is of clinical necessity. Therefore, a phase III, randomized, double-blind trial was performed (June 1988-June 1991) to assess the clinical effectiveness of our vaccinia melanoma oncolysate (VMO) vaccine in stage III melanoma patients.

Suriano R, Rajoria S, George AL, Geliebter J, Tiwari RK, Wallack M.
Mol Clin Oncol. 2013 May;1(3):466-472. Epub 2013 Mar 20.

Learn More

Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines.

Transformation of the pigment producing melanocytes into melanoma is a complex multi-step process involving the enhanced expression of various antigens considered as immunotherapeutic targets.

Suriano R, Rajoria S, L George A, Geliebter J, Wallack M, Tiwari RK.
J Cancer. 2013 Jun 19;4(5):371-82

Learn More

Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.

Metastatic melanoma continues to be one of the most devastating of all cancers. It is a heterogeneous solid tumor whose treatment is challenging and difficult. It afflicts thousands of otherwise healthy patients annually, and clinicians have yet to discover an effective treatment for locally advanced disease.

Kalani AD, Jack A, Montenegro G, Degliuomini J, Wallack MK.
G Ital Dermatol Venereol. 2008 Feb;143(1):59-70. Review.

Learn More

A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model.

This study was conducted to test the efficacy of a new cancer vaccine, composed of dendritic cells (DCs) pulsed with an interleukin-2 gene-encoded vaccinia virus tumor oncolysate (DC-IL-2VCO) in a CC-36 murine colon adenocarcinoma model.

Jack AM, Aydin N, Montenegro G, Alam K, Wallack M.
J Surg Res. 2007 May 15;139(2):164-9.

Learn More

Expression of melanoma-associated antigens in human dendritic cells pulsed with an interleukin-2 gene encoded vaccinia melanoma oncolysate (rIL-2VMO).

Dendritic cells (DCs) possess the unique abilities to initiate a primary immune response and to present antigens to naïve T lymphocytes. Recently, there has been a rapidly growing interest in the use of DCs in active specific immunotherapy (ASI) for the treatment of patients with cancer.

Aydin N, Jack A, Montenegro G, Boyes C, Alam K, Wallack MK.
Cancer Biol Ther. 2006 Dec;5(12):1654-7.

Learn More

The treatment of melanoma with an emphasis on immunotherapeutic strategies.

Melanoma continues to be one of the most difficult to treat of all solid tumors. Many new advances have been made in the surgical management of melanoma, including new guidelines for margins of excision, as well as sentinel node biopsy for the diagnosis of lymph node micrometastases.

Jack A, Boyes C, Aydin N, Alam K, Wallack M.
Surg Oncol. 2006 Jul;15(1):13-24. Epub 2006 Jul 11. Review.

Learn More


Check out our FAQs section to find out answers to your questions.

View Now